Preclinical Science
PRECLINICAL SCIENCE was founded in 2016 by Dr. Roman Föll and Dr. Lars Mecklenburg. It is registered in Münster, Germany, as Föll, Mecklenburg & Partner GmbH. Both founders and newly joined partner Dr. Geertje Lewin bring 30 years of experience in research and development into the business. We have a different focus, though, and supplement our experience with the expertise of partners with whom we maintain a very close working relationship. Our philosophy is a true partnership with our clients and an honest consultation at the highest scientific standard.
Laura-Katharina Bertels
Laura-Katharina Bertels finished her master degree in cellular and molecular biology at the University of Osnabrück in 2019 after obtaining a B.Sc. in Biotechnology from Hochschule Furtwangen University, Germany. Since 2016 she worked as a medical writer in preclinical drug development at Dr. Roman Föll Preclinical Services.


Dr. Roman Föll
General Manager
Dr. Roman Föll studied biology/zoology at the Ludwig-Maximilians-University in Munich, Germany. He made his PhD in biophysics and physiology. Dr. Föll was an assistant professor in zoo physiology at the Westfalian Wilhelms-University in Münster, Germany, and a scientist in inhalation toxicology at Boehringer Ingelheim Pharma KG.
Dr. Erinita Fröhlke
Dr. Erinita Fröhlke studied biology in Berlin, Aachen, Cologne and Heidelberg, Germany, obtained her diploma degree at the German Cancer Institute, Heidelberg and her PhD at the Westfalian Wilhelms-University in Muenster, Germany. She served for 20 years as quality control manager at various CROs and pharmaceutical companies.


Dr. Silvia Guionaud
Dr. Silvia Guionaud received her degree in veterinary sciences and PhD in veterinary pathology from Hannover Veterinary School in Germany. She became a Diplomate of the European College of Veterinary Pathology (ECVP) in 2006.
Dr. Guionaud has a strong background in both investigative and regulatory toxicological pathology and has worked for both small and large biopharmaceutical companies.
Since April 2019, Dr. Guionaud has been working as independent consultant. She is author to numerous scientific publications in the field of toxicological pathology and biomarker development.
Madeleine Joel
Madeleine Joel studied molecular biotechnology (B.Sc.) at the Ruprecht-Karls-University of Heidelberg, Germany and made her bachelor thesis in the field of melanoma immunotherapy at the German Cancer Research Center, Heidelberg, Germany. Afterwards, she studied toxicology (M.Sc.) at the Technical University of Kaiserslautern, Germany and performed her master’s degree in genotoxicology/stem cell research at King’s College London, Great Britain, where she worked afterwards as research assistant.


Prof. Robert Klopfleisch
Robert Klopfleisch studied veterinary medicine at the University of Leipzig and obtained his PhD at the Friedrich-Loeffler-Institute and University Giessen. Robert Klopfleisch is a pathologist, certified by the American College of Veterinary Pathologists. He has extensive experience in the pathology evaluation of preclinical studies and has authored more than 170 publications.
Dr. Geertje Lewin
General Manager
Dr. Geertje Lewin studied ecology and biology in Cambridge, US and Greifswald, Germany and obtained her PhD in zoophysiology. She worked as researcher and lecturer in pharmacology and toxicology at the Westfalian Wilhelms-University in Muenster, Germany. As a study director in reproductive toxicology and risk assessor for chemicals, Dr. Lewin worked at the Fraunhofer Institute for Toxicology and Experimental Medicine, Germany in GLP studies, developed alternative testing methods and new in-vivo/in vitro models.


Dr. Lars Mecklenburg
Co-Founder, currently not contributing to consulting
Dr. Lars Mecklenburg studied veterinary medicine at the Veterinary School in Hannover, Germany. He achieved his PhD in pathology and is certified as a pathologist in Germany. In 2009, Dr. Mecklenburg became a Diplomate of the American College of Veterinary Pathologists (ACVP) and in 2012, he was certified as an Advanced Risk Assessor by the European TRISK program.
Ulrich Schreiber
Ulrich Schreiber studied Chemistry at the Westfalian Wilhelms-University in Muenster, Germany. He finished his Bachelor´s thesis in 2015 in the field of organic synthesis. Afterwards he obtained his MSc in Toxicology at the Charité in Berlin and finished his Master´s thesis in method development for detection of cannabinoids in serum in 2017. Before starting to work as a toxicologist for Preclinical Science in 2019 he worked as a Research Assistant at the Interdisciplinary Center for Clinical Research at the University Hospital in Münster.
